前往印度的《与贸易有关的知识产权协定》之行——诺华公司、专利法与药品可及性 - Suppr

Suppr

超能文献

Taking TRIPS to India--Novartis, patent law, and access to medicines.

作者信息

Mueller Janice M

机构信息

University of Pittsburgh School of Law, Pittsburgh, USA.

出版信息

N Engl J Med. 2007 Feb 8;356(6):541-3. doi: 10.1056/NEJMp068245.

DOI:10.1056/NEJMp068245

PMID:17287473

Abstract

摘要

相似文献

Taking TRIPS to India--Novartis, patent law, and access to medicines.

N Engl J Med. 2007 Feb 8;356(6):541-3. doi: 10.1056/NEJMp068245.

Is India ready to lead the battle for fair access to medicines?

Lancet Oncol. 2013 May;14(6):437. doi: 10.1016/S1470-2045(13)70197-9.

[Novartis should discontinue its patent case in India!].

Lakartidningen. 2007;104(7):524.

TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.

Chic J Int Law. 2002 Spring;3(1):27-46.

Engineered in India--patent law 2.0.

N Engl J Med. 2013 Aug 8;369(6):497-9. doi: 10.1056/NEJMp1304400. Epub 2013 Jul 17.

Final hearings begin in epic legal battle over Novartis drug in India.

BMJ. 2012 Sep 18;345:e6257. doi: 10.1136/bmj.e6257.

Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?

Bull World Health Organ. 2004 Nov;82(11):815-21. Epub 2004 Dec 14.

Amendments to the Canadian Patent Act to address drug access: is help on the way?

Food Drug Law J. 2005;60(3):459-70.

The GO License: only part of the solution.

Health Aff (Millwood). 2008 Jan-Feb;27(1):140-2. doi: 10.1377/hlthaff.27.1.140.

Reforming Canada's Access to Medicines Regime.

CMAJ. 2007 Jul 31;177(3):270-1. doi: 10.1503/cmaj.1070075.

引用本文的文献

Navigating the road toward optimal initial therapy for chronic myeloid leukemia.

Curr Opin Hematol. 2011 Mar;18(2):89-97. doi: 10.1097/MOH.0b013e32834399a5.

TRIPS, the Doha declaration and paragraph 6 decision: what are the remaining steps for protecting access to medicines?

Global Health. 2007 May 24;3:3. doi: 10.1186/1744-8603-3-3.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Taking TRIPS to India--Novartis, patent law, and access to medicines.

作者信息

Mueller Janice M

机构信息

University of Pittsburgh School of Law, Pittsburgh, USA.

出版信息

N Engl J Med. 2007 Feb 8;356(6):541-3. doi: 10.1056/NEJMp068245.

DOI:10.1056/NEJMp068245

PMID:17287473

Abstract

摘要

相似文献

Taking TRIPS to India--Novartis, patent law, and access to medicines.

N Engl J Med. 2007 Feb 8;356(6):541-3. doi: 10.1056/NEJMp068245.

Is India ready to lead the battle for fair access to medicines?

Lancet Oncol. 2013 May;14(6):437. doi: 10.1016/S1470-2045(13)70197-9.

[Novartis should discontinue its patent case in India!].

Lakartidningen. 2007;104(7):524.

TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.

Chic J Int Law. 2002 Spring;3(1):27-46.

Engineered in India--patent law 2.0.

N Engl J Med. 2013 Aug 8;369(6):497-9. doi: 10.1056/NEJMp1304400. Epub 2013 Jul 17.

Final hearings begin in epic legal battle over Novartis drug in India.

BMJ. 2012 Sep 18;345:e6257. doi: 10.1136/bmj.e6257.

Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?

Bull World Health Organ. 2004 Nov;82(11):815-21. Epub 2004 Dec 14.

Amendments to the Canadian Patent Act to address drug access: is help on the way?

Food Drug Law J. 2005;60(3):459-70.

The GO License: only part of the solution.

Health Aff (Millwood). 2008 Jan-Feb;27(1):140-2. doi: 10.1377/hlthaff.27.1.140.

Reforming Canada's Access to Medicines Regime.

CMAJ. 2007 Jul 31;177(3):270-1. doi: 10.1503/cmaj.1070075.

引用本文的文献

Navigating the road toward optimal initial therapy for chronic myeloid leukemia.

Curr Opin Hematol. 2011 Mar;18(2):89-97. doi: 10.1097/MOH.0b013e32834399a5.

TRIPS, the Doha declaration and paragraph 6 decision: what are the remaining steps for protecting access to medicines?

Global Health. 2007 May 24;3:3. doi: 10.1186/1744-8603-3-3.